Non-muscle Invasive Bladder Cancer (NMIBC) Market Analysis, Market Size, Epidemiology, Leading Companies | Companies – ImmunityBio/ Altor Biosciences, Theralase, CG Oncology, Seattle Genetics
DelveInsight has launched a new report on “Non-muscle Invasive Bladder Cancer (NMIBC)-Market Insights, Epidemiology, and Market Forecast-2032”.
DelveInsight’s “Non-muscle Invasive Bladder Cancer (NMIBC)–Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Non-muscle Invasive Bladder Cancer (NMIBC), historical and forecasted epidemiology as well as the Non-muscle Invasive Bladder Cancer (NMIBC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Non-muscle Invasive Bladder Cancer Market Report:
- The total diagnosed prevalent population of NMIBC in the seven major market ranges was 533,263 in 2019, which will increase for the study period i.e., 2019–2032.
- In 2019, the diagnosed prevalent population of low-grade NMIBC patients was 136,822 and high-grade NMIBC patients were 76,962 in the US, which is anticipated to increase in the forecast period.
- In Japan, the diagnosed prevalent population of NMIBC was 74,691 in 2019.
Key benefits of the report:
1.The Non-muscle Invasive Bladder Cancer (NMIBC) market report covers a descriptive overview and comprehensive insight of the Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology and Non-muscle Invasive Bladder Cancer (NMIBC) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2.The Non-muscle Invasive Bladder Cancer (NMIBC) market report provides insights into the current and emerging therapies.
3.Non-muscle Invasive Bladder Cancer (NMIBC) market report provides a global historical and forecasted market covering drug outreach in 7MM.
4.The Non-muscle Invasive Bladder Cancer (NMIBC) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Non-muscle Invasive Bladder Cancer (NMIBC) market.
Request for sample pages: https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
Non-muscle Invasive Bladder Cancer (NMIBC): Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. Bladder cancer is the 6th most common cancer in the United States. Nearly 84,000 people will be diagnosed in the United States with bladder cancer in 2022.
The key players involved in the Non-muscle Invasive Bladder Cancer (NMIBC) Market:
- FKD Therapies Oy/ Ferring Pharmaceuticals
- Merck
- ViventiaBio/Sesen Bio
- ImmunityBio/ Altor Biosciences
- Theralase
- CG Oncology
- Seattle Genetics
The launch of the emerging therapies is expected to significantly impact the Non-muscle Invasive Bladder Cancer (NMIBC) treatment scenario in the upcoming years:-
Drug covered
- Adstiladrin
- Keytruda
- Vicinium
- N-803 (ALT-803)
- TLD-1433
- CG0070
- Padcev
Request a free sample report @https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Non-muscle Invasive Bladder Cancer (NMIBC) Patient Share (%) Overview at a Glance
5. Non-muscle Invasive Bladder Cancer (NMIBC) Market Overview at a Glance
6. Non-muscle Invasive Bladder Cancer (NMIBC) Disease Background and Overview
7. Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-muscle Invasive Bladder Cancer (NMIBC)
9. Non-muscle Invasive Bladder Cancer (NMIBC) Current Treatment and Medical Practices
10. Unmet Needs
11. Non-muscle Invasive Bladder Cancer (NMIBC) Emerging Therapies
12. Non-muscle Invasive Bladder Cancer (NMIBC) Market Outlook
13. Country-Wise Non-muscle Invasive Bladder Cancer (NMIBC) Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Non-muscle Invasive Bladder Cancer (NMIBC) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/